David Andrés Perez-Martinez

Dr. David Andrés Perez-Martinez

Hospital Universitario 12 De Octubre, Madrid, Spain
+1
orcid

Research Focus & Metrics

Academic Career Length

28Years (1999-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
8 April 2020 in Biomolecules
Verified
Journal Article
Open access
PDF file
MSMarta González Sánchez
Marta González Sánchez
JJJavier Jiménez
Javier Jiménez
ANAranzazu Narvaez
Aranzazu Narvaez
DADesiree Antequera
Desiree Antequera
SLSara Llamas-Velasco
Sara Llamas-Velasco
Eva M. CarroEva M. Carro
Eva M. Carro
Kynurenic acid (KYNA) is a product of the tryptophan (TRP) metabolism via the kynurenine pathway (KP). This pathway is activated in neurodegenerative disorders, such as Alzheimer´s disease (AD). KYNA is primarily produced by astrocytes and is considered neuroprotective. Thus, altered KYNA levels may suggest an inflammatory response. Very recently, significant increases in KYNA levels were reported in cerebrospinal fluid (CSF) from AD patients compared with normal controls. In this study, we assessed the accuracy of KYNA in CSF for the classification of patients with AD, cognitively healthy controls, and patients with a variety of other neurodegenerative diseases, including frontotemporal dementia (FTD), amyotrophic lateral sclerosis (ALS), and progressive supranuclear palsy (PSP). Averaged KYNA concentration in CSF was higher in patients with AD when compared with healthy subjects and with all the other differentially diagnosed groups. There were no significant differences in KYNA levels in CSF between any other neurodegenerative groups and controls. These results suggest a specific increase in KYNA concentration in CSF from AD patients not seen in other neurodegenerative diseases.

2 February 2015 in JMIR mHealth and uHealth
Verified
Journal Article
Open access
ARAlejandr Rodríguez-Molinero
Alejandr Rodríguez-Molinero
ASAlbert Samà
Albert Samà
DPDavid Andrés Perez-Martinez
David Andrés Perez-Martinez
CLCarlos Pérez López
Carlos Pérez López
JRJaume Romagosa
Jaume Romagosa
ACAndreu Catalá
Andreu Catalá
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

25 April 2018 in JMIR Rehabilitation and Assistive Technologies
Verified
Journal Article
Open access
ARAlejandr Rodríguez-Molinero
Alejandr Rodríguez-Molinero
CLCarlos Pérez López
Carlos Pérez López
ASAlbert Samà
Albert Samà
EMEva de Mingo
Eva de Mingo
DMDaniel Rodriguez Martin
Daniel Rodriguez Martin
AMAndreu Català Mallofré
Andreu Català Mallofré
Journal of Medical Internet Research - International Scientific Journal for Medical Research, Information and Communication on the Internet

Verified
Journal Article
Open access
PDF file
MAMaria Isabel Alvarez-Mora
Maria Isabel Alvarez-Mora
VPVICTOR BLANCO PALMERO
VICTOR BLANCO PALMERO
JQJuan Francisco Quesada-Espinosa
Juan Francisco Quesada-Espinosa
AAANA ARTECHE
ANA ARTECHE
SLSara Llamas-Velasco
Sara Llamas-Velasco
MMMarta Moreno-Garcia
Marta Moreno-Garcia
In the last few years, the SORL1 gene has been strongly implicated in the development of Alzheimer’s disease (AD). We performed whole-exome sequencing on 37 patients with early-onset dementia or family history suggestive of autosomal dominant dementia. Data analysis was based on a custom panel that included 46 genes related to AD and dementia. SORL1 variants were present in a high proportion of patients with candidate variants (15%, 3/20). We expand the clinical manifestations associated with the SORL1 gene by reporting detailed clinical and neuroimaging findings of six unrelated patients with AD and SORL1 mutations. We also present for the first time a patient with the homozygous truncating variant c.364C>T (p.R122*) in SORL1, who also had severe cerebral amyloid angiopathy. Furthermore, we report neuropathological findings and immunochemistry assays from one patient with the splicing variant c.4519+5G>A in the SORL1 gene, in which AD was confirmed by neuropathological examination. Our results highlight the heterogeneity of clinical presentation and familial dementia background of SORL1-associated AD and suggest that SORL1 might be contributing to AD development as a risk factor gene rather than as a major autosomal dominant gene.

12 December 2025 in Journal of Alzheimer’s Disease
Verified
Journal Article
Closed access
AVAlberto Villarejo-Galende
Alberto Villarejo-Galende
MSMarta González Sánchez
Marta González Sánchez
AHAmaya Hilario
Amaya Hilario
SLSara Llamas-Velasco
Sara Llamas-Velasco
EMEstrella Morenas-Rodríguez
Estrella Morenas-Rodríguez
VPVICTOR BLANCO PALMERO
VICTOR BLANCO PALMERO
Background: Amyloid-related imaging abnormalities (ARIA) are a recognized complication of anti-amyloid monoclonal antibodies for Alzheimer's disease (AD). While typically asymptomatic, a subset of patients develops severe clinical symptoms and radiological findings requiring intensive management. Data on their presentation, treatment, and outcomes remain limited. Objective: We report two cases and analyze the clinical features of all published cases of severe symptomatic ARIA, with a focus on associated risk factors, therapeutic approaches, and patient outcomes. Methods: We report two cases of severe symptomatic ARIA in patients treated with gantenerumab. A systematic review was conducted following PRISMA guidelines using MEDLINE, Web of Science, and manual reference screening. We included case reports and series providing individual-level data on symptomatic ARIA episodes classified as severe by clinical criteria. Demographic, genetic, clinical, radiological, therapeutic, and outcome data were extracted. Results: Thirty-six cases were included (2 new and 34 from 21 publications). Fifteen cases were associated with lecanemab, 10 with gantenerumab, 6 with donanemab, and 5 with other antibodies. APOE ε4 was present in 62.5%, including 10 ε4/ε4 homozygotes. Baseline MRI showed hemorrhagic markers in 10 cases, including superficial siderosis in 2 of the 5 patients with isolated macrohemorrhages. Most episodes occurred within 6 months of treatment. Symptoms included altered consciousness (75%), focal deficits (66.7%), seizures (38.9%), and headache (36.1%). ARIA-E resolved in all non-fatal cases. Corticosteroids were used in 72%. Among the patients whose outcome data were available, 15 patients recovered completely, 10 had persistent deficits, and 10 died. Conclusions: Severe symptomatic ARIA is a rare but serious adverse effect of anti-amyloid therapy. Standardized diagnostic and therapeutic guidelines are needed to minimize ARIA-related morbidity and mortality. PROSPERO registration no. CRD420251055067

27 August 2025 in Revista De Neurologia
Verified
Journal Article
Open access
DPDavid Andrés Perez-Martinez
David Andrés Perez-Martinez
Introduction: The advancement of artificial intelligence (AI), particularly generative AI, has significantly transformed the field of medicine, impacting healthcare delivery, medical education, and research. While the opportunities are substantial, the implementation of AI also raises important ethical and technical challenges, including risks related to data bias, the potential erosion of clinical skills, and concerns about information privacy. Development: AI has demonstrated great potential in optimizing both clinical and educational processes. However, its operation based on probabilistic prediction is inherently prone to errors and biases. Healthcare professionals must be aware of these limitations and advocate for a transparent, responsible, and safe integration of AI, while maintaining full ethical and legal responsibility for clinical decisions. It is essential to safeguard traditional clinical competencies and prioritize the use of AI in automating low-value, repetitive tasks. In biomedical research, transparency and independent validation are crucial to ensure the reproducibility of findings. Similarly, in medical education, structured training in AI is vital to enable professionals to apply these tools safely and effectively in clinical practice. Conclusions: Generative AI offers a transformative potential for medicine, but its adoption must be guided by rigorous ethical standards. Comprehensive training, risk mitigation, and the preservation of core clinical skills are essential pillars for its responsible implementation. This transformation must be led by the medical profession to ensure a patient-centered approach to care.